Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

MF Bastide, WG Meissner, B Picconi, S Fasano… - Progress in …, 2015 - Elsevier
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

MA Cenci - Frontiers in neurology, 2014 - frontiersin.org
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's
disease (PD) for over 40 years. However, the response to this treatment changes with …

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients

M Politis, K Wu, C Loane, DJ Brooks… - The Journal of …, 2014 - Am Soc Clin Investig
Levodopa-induced dyskinesias (LIDs) are the most common and disabling adverse motor
effect of therapy in Parkinson's disease (PD) patients. In this study, we investigated …

Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications

P De Deurwaerdère, G Di Giovanni - Progress in neurobiology, 2017 - Elsevier
Since their discovery in the mammalian brain, it has been apparent that serotonin (5-HT)
and dopamine (DA) interactions play a key role in normal and abnormal behavior …

Molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in Parkinson's disease: a perspective through preclinical and clinical evidence

R Bandopadhyay, N Mishra, R Rana, G Kaur… - Frontiers in …, 2022 - frontiersin.org
Parkinson's disease (PD) is the second leading neurodegenerative disease that is
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …

Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry

P De Deurwaerdère, G Di Giovanni, MJ Millan - Progress in neurobiology, 2017 - Elsevier
Though a multi-facetted disorder, Parkinson's disease is prototypically characterized by
neurodegeneration of nigrostriatal dopaminergic neurons of the substantia nigra pars …

Genetically modified pig models for neurodegenerative disorders

IE Holm, AKO Alstrup, Y Luo - The Journal of pathology, 2016 - Wiley Online Library
Increasing incidence of neurodegenerative disorders such as Alzheimer's disease and
Parkinson's disease has become one of the most challenging health issues in ageing …

Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease

C Miguelez, T Morera-Herreras, M Torrecilla… - Frontiers in neural …, 2014 - frontiersin.org
The neurotransmitter serotonin (5-HT) has a multifaceted function in the modulation of
information processing through the activation of multiple receptor families, including G …

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat

H Iderberg, AC McCreary, MA Varney, MS Kleven… - Experimental …, 2015 - Elsevier
Abstract l-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces
troublesome dyskinesia after prolonged treatment. This is associated with the 'false …

Activity of serotonin 5-HT1A receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia

H Iderberg, AC McCreary, MA Varney, MA Cenci… - …, 2015 - Elsevier
Serotonin 5-HT 1A receptor agonists reduce l-DOPA-induced dyskinesia (LID) in animal
models of Parkinson's disease (PD). Here, we compared the effects of novel 5-HT 1A …